CD8A and hepatocellular carcinoma: In HCC, drugs such as Nilotinib and ABT-737 which target SOAT1, have been found to alter cholesterol metabolism and enhance CD8+ T cells and neutrophils killing ability, thus inhibiting HCC growth [129, 144, 145].